Several other research firms have also recently weighed in on NLNK. Zacks Investment Research cut NewLink Genetics from a buy rating to a hold rating in a research report on Thursday, January 4th. Stifel Nicolaus increased their price objective on NewLink Genetics from $25.00 to $29.00 and gave the company a buy rating in a research report on Friday, November 3rd. Jefferies Group reduced their price objective on NewLink Genetics from $26.00 to $25.00 and set a buy rating for the company in a research report on Friday, November 3rd. Bank of America initiated coverage on NewLink Genetics in a research report on Friday, October 13th. They issued a buy rating and a $22.00 price objective for the company. Finally, ValuEngine cut NewLink Genetics from a sell rating to a strong sell rating in a research report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $23.29.
NewLink Genetics (NASDAQ NLNK) traded up $0.14 on Monday, hitting $8.58. The stock had a trading volume of 739,632 shares, compared to its average volume of 1,120,270. NewLink Genetics has a 12 month low of $5.90 and a 12 month high of $25.17. The company has a market capitalization of $310.78, a PE ratio of -3.52 and a beta of 1.10.
WARNING: “NewLink Genetics (NLNK) Given a $26.00 Price Target at Cantor Fitzgerald” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://weekherald.com/2018/01/12/newlink-genetics-nlnk-given-a-26-00-price-target-at-cantor-fitzgerald.html.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.